Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
STOCKS
Capricor Therapeutics Stock Surging on Positive Muscular Dystrophy Trial Results
By Amanda Schiavo
Apr 25, 2017 10:07 AM EDT
PRESS RELEASES
Capricor Therapeutics Announces Publication Demonstrating Methods For Enhanced Potency Of Cardiosphere-Derived Exosomes
By GlobeNewswire
Jan 19, 2021 9:15 AM EST
PRESS RELEASES
Capricor Collaborates With Lonza For The Development Of CAP-1002, Its Cell Therapy Candidate For The Treatment Of Duchenne Muscular Dystrophy And Other Indications
By GlobeNewswire
Jan 12, 2021 9:05 AM EST
PRESS RELEASES
Capricor Therapeutics Announces DSMB Recommendation To Continue Phase II INSPIRE Trial For Severe COVID-19 Patients
By GlobeNewswire
Dec 29, 2020 9:15 AM EST
PRESS RELEASES
Capricor Therapeutics Commences Dosing Patients In Phase 2 Trial Of CAP-1002 In Patients With Severe COVID-19
By GlobeNewswire
Nov 24, 2020 7:30 AM EST
PRESS RELEASES
Capricor Therapeutics Announces Positive Preclinical Data For Multivalent Exosome-mRNA Vaccine For COVID-19
By GlobeNewswire
Nov 9, 2020 9:15 AM EST
PRESS RELEASES
Capricor Therapeutics To Present Results From The HOPE-2 Trial With CAP-1002 In Duchenne Muscular Dystrophy At The International World Muscle Society Virtual Congress 2020
By GlobeNewswire
Sep 23, 2020 9:25 AM EDT
PRESS RELEASES
Capricor Therapeutics Announces U.S. FDA Acceptance Of Its IND Application For A Phase 2 Clinical Trial Of CAP-1002 In Patients With COVID-19
By GlobeNewswire
Aug 25, 2020 9:15 AM EDT
PRESS RELEASES
Capricor To Participate In Maxim Group's COVID-19 Virtual Conference Series On May 27, 2020
By GlobeNewswire
May 26, 2020 9:25 AM EDT
PRESS RELEASES
New Capricor Data Reports 100 Percent Survival In Critical COVID-19 Patients Treated With CAP-1002
By GlobeNewswire
Apr 29, 2020 9:15 AM EDT
PRESS RELEASES
Capricor Initiates Compassionate Use Program For Severe COVID-19 Patients Using CAP-1002, Its Novel Cell Therapy
By GlobeNewswire
Apr 3, 2020 8:00 AM EDT
PRESS RELEASES
Capricor Therapeutics Announces Strategic Plan For Exosome Platform Technology Products Expansion
By GlobeNewswire
Mar 17, 2020 8:00 AM EDT
STOCKS
Capricor Therapeutics Stock Surging on Positive Muscular Dystrophy Trial Results
By Amanda Schiavo
Apr 25, 2017 10:07 AM EDT
INVESTING
Four Stem-Cell Stocks With Promise
By Gregg Greenberg
Jul 30, 2015 2:19 PM EDT
VIDEO
Pluristem, Capricor Lead Regenerative Space Says Raymond James Analyst
By Gregg Greenberg
Jul 30, 2015 12:37 PM EDT
